Til hovedinnhold

Contrast enhanced MRI of preclinical cancer models

Godkjenningsdato
Godkjent fra
Godkjent til
Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) is an essential tool for cancer diagnosis and management. Still, accurate detection of cancer and prediction/evaluation of treatment response remain significant challenges. The aim of this project is to develop better contrast-enhanced MRI methods that more accurately characterize tumor aggressiveness and are more sensitive to treatment response. The methods we develop preclinically in animal experiments can then be tested in clinical trials and result in improved clinical care.

We will use mouse models of three different cancers: breast, ovarian, and prostate. For each model, the mice will be divided into three groups of 10: one control group and two treatment groups. Thus, a total of 90 mice will be included in this study. The animals cannot be replaced because the purpose of the study is to evaluate in vivo, clinically translatable imaging protocols. However, the number of animals has been reduced by first testing the protocols on phantoms and choosing group sizes based on our own extensive experience with these animal models. The mice will be housed in groups and provided environmental enrichment, and food and water ad libitum. The mice will be anesthetized during all experimental procedures to minimize their discomfort. Their welfare will be closely monitored throughout the duration of the study, and they will be promptly euthanized when humane endpoints are reached.